BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 26189955)

  • 1. Green tea component epigallocatechin-3-gallate decreases expression of osteopontin via a decrease in mRNA half-life in cell lines of metastatic hepatocellular carcinoma.
    Zapf MA; Kothari AN; Weber CE; Arffa ML; Wai PY; Driver J; Gupta GN; Kuo PC; Mi Z
    Surgery; 2015 Oct; 158(4):1039-47; discussion 1047-8. PubMed ID: 26189955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostanoid EP1 receptor as the target of (-)-epigallocatechin-3-gallate in suppressing hepatocellular carcinoma cells in vitro.
    Jin J; Chang Y; Wei W; He YF; Hu SS; Wang D; Wu YJ
    Acta Pharmacol Sin; 2012 May; 33(5):701-9. PubMed ID: 22555372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA stability regulates differential expression of the metastasis protein, osteopontin, in hepatocellular cancer.
    Emani S; Zhang J; Guo L; Guo H; Kuo PC
    Surgery; 2008 Jun; 143(6):803-12. PubMed ID: 18549897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EF1A1-actin interactions alter mRNA stability to determine differential osteopontin expression in HepG2 and Hep3B cells.
    Zhang J; Guo H; Mi Z; Gao C; Bhattacharya S; Li J; Kuo PC
    Exp Cell Res; 2009 Jan; 315(2):304-12. PubMed ID: 19026636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Epigallocatechin-3-gallate induces apoptosis in human hepatocellular carcinoma cells].
    Chen XL; Wang Q; Cao LQ; Huang XH; Fu XH; Tan HX; Zhen MC; Chen JS
    Zhonghua Yi Xue Za Zhi; 2008 Sep; 88(36):2524-8. PubMed ID: 19080641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interference of osteopontin expression inhibits the invasion and metastasis of human hepatocellular carcinoma cell lines].
    Lin F; Li YY; Xia JT; Wen MJ; Lai YY; Cai WS; Wu ZF; Fan SF
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):422-5. PubMed ID: 19567019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins.
    Nishikawa T; Nakajima T; Moriguchi M; Jo M; Sekoguchi S; Ishii M; Takashima H; Katagishi T; Kimura H; Minami M; Itoh Y; Kagawa K; Okanoue T
    J Hepatol; 2006 Jun; 44(6):1074-82. PubMed ID: 16481065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luteolin induces caspase-dependent apoptosis via inhibiting the AKT/osteopontin pathway in human hepatocellular carcinoma SK-Hep-1 cells.
    Im E; Yeo C; Lee EO
    Life Sci; 2018 Sep; 209():259-266. PubMed ID: 30107166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Impact of epigallocatechin gallate on gene expression profiles of human hepatocellular carcinoma cell lines BEL7404/ADM and BEL7402/5-FU].
    Tang HH; Zhou M; Liang G
    Ai Zheng; 2008 Oct; 27(10):1056-64. PubMed ID: 18851785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteopontin regulates epithelial mesenchymal transition-associated growth of hepatocellular cancer in a mouse xenograft model.
    Bhattacharya SD; Mi Z; Kim VM; Guo H; Talbot LJ; Kuo PC
    Ann Surg; 2012 Feb; 255(2):319-25. PubMed ID: 22241292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteopontin promotes hepatocellular carcinoma invasion by up-regulating MMP-2 and uPA expression.
    Chen RX; Xia YH; Xue TC; Ye SL
    Mol Biol Rep; 2011 Aug; 38(6):3671-7. PubMed ID: 21104439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thirty-kilodalton Tat-interacting protein suppresses tumor metastasis by inhibition of osteopontin transcription in human hepatocellular carcinoma.
    Zhao J; Lu B; Xu H; Tong X; Wu G; Zhang X; Liang A; Cong W; Dai J; Wang H; Wu M; Guo Y
    Hepatology; 2008 Jul; 48(1):265-75. PubMed ID: 18537194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Identification of metastasis-related osteopontin expression and glycosylation in hepatocellular carcinoma].
    Sun HY; Li Y; Guo K; Kang XN; Sun C; Liu YK
    Zhonghua Gan Zang Bing Za Zhi; 2011 Dec; 19(12):904-7. PubMed ID: 22525502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigallocatechin-3-Gallate Upregulates miR-221 to Inhibit Osteopontin-Dependent Hepatic Fibrosis.
    Arffa ML; Zapf MA; Kothari AN; Chang V; Gupta GN; Ding X; Al-Gayyar MM; Syn W; Elsherbiny NM; Kuo PC; Mi Z
    PLoS One; 2016; 11(12):e0167435. PubMed ID: 27935974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma.
    Takafuji V; Forgues M; Unsworth E; Goldsmith P; Wang XW
    Oncogene; 2007 Sep; 26(44):6361-71. PubMed ID: 17452979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-metastatic and differential effects on protein expression of epigallocatechin-3-gallate in HCCLM6 hepatocellular carcinoma cells.
    Zhang Y; Owusu L; Duan W; Jiang T; Zang S; Ahmed A; Xin Y
    Int J Mol Med; 2013 Oct; 32(4):959-64. PubMed ID: 23863984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-C chemokine receptor type 1 mediates osteopontin-promoted metastasis in hepatocellular carcinoma.
    Zhu Y; Gao XM; Yang J; Xu D; Zhang Y; Lu M; Zhang Z; Sheng YY; Li JH; Yu XX; Zheng Y; Dong QZ; Qin LX
    Cancer Sci; 2018 Mar; 109(3):710-723. PubMed ID: 29285854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemopreventive and hepatoprotective effects of Epigallocatechin-gallate against hepatocellular carcinoma: role of heparan sulfate proteoglycans pathway.
    Darweish MM; Abbas A; Ebrahim MA; Al-Gayyar MM
    J Pharm Pharmacol; 2014 Jul; 66(7):1032-45. PubMed ID: 24611903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteopontin in hepatocellular carcinoma: A possible biomarker for diagnosis and follow-up.
    Cabiati M; Gaggini M; Cesare MM; Caselli C; De Simone P; Filipponi F; Basta G; Gastaldelli A; Del Ry S
    Cytokine; 2017 Nov; 99():59-65. PubMed ID: 28711012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis.
    Shirakami Y; Shimizu M; Adachi S; Sakai H; Nakagawa T; Yasuda Y; Tsurumi H; Hara Y; Moriwaki H
    Cancer Sci; 2009 Oct; 100(10):1957-62. PubMed ID: 19558547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.